



IFW

PATENT  
Customer No. 22,852  
Attorney Docket No. 08201.0038-00000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)	
	)	
Dinah W.Y. SAH <i>et al.</i>	)	Group Art Unit: Not Yet Assigned
	)	
Application No.: 10/784,004	)	Examiner: Not Yet Assigned
	)	
Filed: February 20, 2004	)	
	)	
For: SURROGATE MARKERS OF	)	Confirmation No.: Not Yet Assigned
NEUROPATHIC PAIN	)	

Commissioner for Patents-  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicants bring to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed foreign and non-patent literature documents are attached. Each document listed in this Information Disclosure Statement was first cited in a communication from the PCT in a counterpart foreign application, and this Information Disclosure Statement is being filed within thirty days of the mailing date of that communication. In accordance with 37 C.F.R. § 1.704(d), no negative patent term adjustment consequences will apply to this Information Disclosure Statement.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: July 29, 2005

By:   
Leslie A. McDonell  
Reg. No. 34,872

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/784,004
				Filing Date	February 20, 2004
				First Named Inventor	Dinah W.Y. Sahn
				Art Unit	
				Examiner Name	
Sheet	1	of	1	Attorney Docket Number	08201.0038-00000

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.**

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation <sup>6</sup>
		WO 01/51667 A2	07-19-2001	INTEGRIDERM, LLC	page 3, line 24 - page 4, line 12	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation <sup>6</sup>
		Partial International Search Report, PCT/US2005/005250, June 30, 2005	
		Diemel et al., "Increased Nerve Growth Factor mRNA in Lateral Calf Skin Biopsies from Diabetic Patients", <i>Diabetic Medicine: A Journal of the British Diabetic Association</i> , 16(2):113-118 (1999)	
		Ito et al., "Codon 54 Polymorphism of the Fatty Acid Binding Protein Gene and Insulin Resistance in the Japanese Population", <i>Diabetic Medicine: A Journal of the British Diabetic Association</i> , 16(2):119-124 (1999)	
		Lauria et al., "Axonal Swellings Predict the Degeneration of Epidermal Nerve Fibers in Painful Neuropathies", <i>Neurology</i> , 61:631-636 (2003)	
		Manni et al., "Cholecystokinin-8 Enhances Nerve Growth Factor Synthesis and Promotes Recovery of Capsaicin-Induced Sensory Deficit", <i>British Journal of Pharmacology</i> , 129(4):744-750 (2000)	
		Terenghi et al., "trkA and trkC Expression is Increased in Human Diabetic Skin", <i>Neuroscience Letters</i> 228(1):33-36 (1997)	
		Yasuda et al., "Diabetic Neuropathy and Nerve Regeneration", <i>Progress in Neurobiology</i> , 69:229-285 (2003)	

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.